The critical role of platelet adenylyl cyclase 6 in hemostasis and thrombosis
Journal of Thrombosis and Haemostasis · 2025
DOI: 10.1016/j.jtha.2025.02.045 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2025. Verfasst von Beth A Webb und 9 weiteren Autor:innen. Beteiligte Einrichtung: Discovery and Translational Science Department, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK. Hauptthemen laut MEDLINE: Thrombosis, Hemostasis, Adenylyl Cyclases, Blood Platelets. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: British Heart Foundation.
Abstract (Originalsprache)
BACKGROUND: Platelet activation is constrained by endothelial-derived prostacyclin (PGI2) through cyclic adenosine-3',5'-monophosphate (cAMP) signaling involving multiple isoforms of adenylyl cyclase (AC). The roles of specific AC isoforms in controlling hemostasis remain unclear and require clarification. OBJECTIVES: To understand the specific contribution of AC6 in platelet hemostatic and thrombotic function. METHODS: A platelet-specific AC6 knockout mouse was generated. Biochemical approaches were used to determine intracellular signaling, with flow cytometry, tail bleeding time assays, and in vivo thrombosis by ferric chloride were used to measure the hemostatic and thrombotic importance of platelet AC6. RESULTS: Loss of AC6 resulted in diminished accumulation of platelet cAMP in response to PGI2, while basal cAMP was unaffected. We found no differences in phosphodiesterase 3A activity, suggesting the defect was in generation rather than hydrolysis of cAMP. Consistent with this, phosphorylation of protein kinase A substrates, vasodilator-stimulated phosphoprotein, and glycogen synthase kinase were diminished but not ablated. Functional studies demonstrated that the inhibition of thrombin-induced fibrinogen binding and P-selectin expression by PGI2 was severely compromised, while inhibition of glycoprotein VI-mediated platelet activation was largely unaffected. Under conditions of flow formed stable thrombi, but in the absence of AC6, thrombi were insensitive to PGI2. Diminished in vivo sensitivity to PGI2 manifested as significantly reduced tail bleeding and accelerated occlusive arterial thrombus formation in response to vascular injury that were highly unstable and prone to embolization in AC6 knockout mice. CONCLUSION: These data demonstrate that AC6 is linked directly to PGI2-mediated platelet inhibition and regulation of hemostasis and thrombosis in vivo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Discovery and Translational Science Department, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.
- Discovery and Translational Science Department, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK. Electronic address: k.naseem@leeds.ac.uk.
Förderung
- British Heart Foundation
Zitieren
APA
Webb, B. A., Cheah, L. T., Khalil, J. S., Hindle, M. S., McKay, M., Turner, N. A., Kearney, M. T., Ariens, R. A. S., Duval, C., & Naseem, K. M. (2025). The critical role of platelet adenylyl cyclase 6 in hemostasis and thrombosis. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2025.02.045
Vancouver
Webb BA, Cheah LT, Khalil JS, Hindle MS, McKay M, Turner NA, et al. The critical role of platelet adenylyl cyclase 6 in hemostasis and thrombosis. Journal of Thrombosis and Haemostasis. 2025. doi:10.1016/j.jtha.2025.02.045
BibTeX
@article{Webb2025,
author = {Webb, Beth A and Cheah, Lih T and Khalil, Jawad S and Hindle, Matthew S and McKay, Mary and Turner, Neil A and Kearney, Mark T and Ariens, Robert A S and Duval, Cedric and Naseem, Khalid M},
title = {The critical role of platelet adenylyl cyclase 6 in hemostasis and thrombosis},
journal = {Journal of Thrombosis and Haemostasis},
year = {2025},
doi = {10.1016/j.jtha.2025.02.045}
}
EUVIMED